Your SlideShare is downloading. ×
04.15.09: Biopreparedness
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.

Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

04.15.09: Biopreparedness


Published on

Slideshow is from the University of Michigan Medical …

Slideshow is from the University of Michigan Medical
School's M1 Infectious Disease / Microbiology sequence

View additional course materials on Open.Michigan:

  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide


  • 1. Author(s): Sandro Cinti, M.D., 2009License: Unless otherwise noted, this material is made available under the terms ofthe Creative Commons Attribution – Share Alike 3.0 License: have reviewed this material in accordance with U.S. Copyright Law and have tried to maximize your ability to use,share, and adapt it. The citation key on the following slide provides information about how you may share and adapt thismaterial.Copyright holders of content included in this material should contact with any questions,corrections, or clarification regarding the use of content.For more information about how to cite these materials visit medical information in this material is intended to inform and educate and is not a tool for self-diagnosis or areplacement for medical evaluation, advice, diagnosis or treatment by a healthcare professional. Please speak to yourphysician if you have questions about your medical condition.Viewer discretion is advised: Some medical content is graphic and may not be suitable for all viewers.
  • 2. Citation Key for more information see: + Share + Adapt { Content the copyright holder, author, or law permits you to use, share and adapt. } Public Domain – Government: Works that are produced by the U.S. Government. (17 USC § 105) Public Domain – Expired: Works that are no longer protected due to an expired copyright term. Public Domain – Self Dedicated: Works that a copyright holder has dedicated to the public domain. Creative Commons – Zero Waiver Creative Commons – Attribution License Creative Commons – Attribution Share Alike License Creative Commons – Attribution Noncommercial License Creative Commons – Attribution Noncommercial Share Alike License GNU – Free Documentation LicenseMake Your Own Assessment { Content Open.Michigan believes can be used, shared, and adapted because it is ineligible for copyright. } Public Domain – Ineligible: Works that are ineligible for copyright protection in the U.S. (17 USC § 102(b)) *laws in your jurisdiction may differ { Content Open.Michigan has used under a Fair Use determination. } Fair Use: Use of works that is determined to be Fair consistent with the U.S. Copyright Act. (17 USC § 107) *laws in your jurisdiction may differ Our determination DOES NOT mean that all uses of this 3rd-party content are Fair Uses and we DO NOT guarantee that your use of the content is Fair. To use this content you should do your own independent analysis to determine whether or not your use will be Fair.
  • 3. Biopreparedness M1 Infectious Diseases Sequence Sandro CintiSpring 2009
  • 4. Stadium: 1000Faces, wikimedia commons 4Airplane: Gautherie, wikimedia commons
  • 5. What is Bioterrorism? 5
  • 6. •  Bioterrorism is the malevolent use of viruses, bacteria, fungi or toxins to produce death or disease in humans, animals or plants. 6
  • 7. Any Examples of Bioterrorism? 7
  • 8. •  1360 – Plague victims bodies thrown over besieged city s walls•  1763 – Europeans give smallpox infected blankets to Native Americans•  1984 – Bhagwan Shree Rajneesh contaminates food with Salmonella to win election•  1994 – Shoko Assahara group attack Tokyo subway with sarin gas•  2001 – Anthrax 8 Admin-2000, wikimedia commons
  • 9. The 1979 Sverdlovsk Anthrax Outbreak Other images of Sverdlovsk facility removed See: UCLA Department of Epidemiology 9
  • 10. Why use biological weapons? 10
  • 11. Why Use Biological Weapons?•  Cheap-800 X less than nucs•  Easy to acquire –  Dual use –  Web-based information•  High Fatality –  100 kg anthrax could kill 3 million (OTA report, 1993)•  High Panic factor 11
  • 12. What makes a good bioweapon? 12
  • 13. USDA, HHS 13
  • 14. Category A Biological Agents•  Variola major (Smallpox)•  Bacillus anthracis (Anthrax)•  Yersinia pestis (Plague)•  Francisella tularensis (Tularemia)•  Botulinum toxin (Botulism)•  Filoviruses and Arenaviruses (Viral hemorrhagic fevers) 14
  • 15. Anthrax- Bacillus anthracis Cutaneous GastrointestinalInhalational 15 Sources Undetermined (All other images)
  • 16. Anthrax•  Spore former•  Not transmissible person-person•  Inhalational-high mortality (50-90%) –  2-3 IV antibiotics•  Prophylaxis- ciprofloxacin, doxycycline-60 days 16
  • 17. Tularemia CDC Source Undetermined Cutaneous• G(-) Coccobacillus• 1-2 organisms can cause infection Cornell University Medical College• Not person-person spread• Tx-aminoglycosides, cipro,doxycycline 17
  • 18. Botulinum Toxin•  Made by the bacterium Clostridium botulinum•  Most toxic substance on earth - food poisoning ( 0.1 ug lethal dose)•  Weaponizable and aerosolizable (air & food supplies)•  BoTox also used to medically, anti-wrinkle•  Secreted protein neurotoxin causing flaccid paralysis•  Death due to asphyxiation Image of Botox injection removed Image available here: C. botulinum Cosmetic improvements are NOT Source Undetermined bioterrorism 18
  • 19. Hemorrhagic Viruses•  Ebola, Marburg, Yellow Fever, Lassa•  Viral syndrome with hemorrhagic complications•  High fatalities with Ebola (80%) Dr. Lyle Conrad, Joel G. Breman, CDC PHIL #7201•  No treatments, few vaccines (YF)•  Person-person spread Source Undetermined 19
  • 20. Plague-Yersinia pestis Source Undetermined World Health Organization, CDC PHIL #463 CDC PHIL #2047 BubonicSource Undetermined 20
  • 21. Septicemic PlagueSource Undetermined Source Undetermined 21
  • 22. Pneumonic Plague•  Most likely form in BT•  Mortality 80-90%•  Person-person transmission•  Tx- Streptomycin, IV ciprofloxicin or doxycycline Source Undetermined•  Prophylaxis- oral cipro or doxy 22
  • 23. 18th century London newspaper 23
  • 24. How would BT agents be disseminated? 24
  • 25. •  Food•  Water•  Zoonotic•  Aerosol 25
  • 26. How would a BT attack be detected? 26
  • 27. Clues to a BT Attack•  A large number of ill persons presenting at the same time with a similar disease, especially the following syndromes: o  Flaccid paralysis (botulinum toxin) o  Hemorrhagic fevers (Ebola, Lassa fever) o  Vesicular/pustular rash with considerable mortality (smallpox) o  Influenza-like illness associated with a widened mediastinum on chest X-ray and/or meningitis (anthrax) o  Pneumonia with painful lymphadenopathy (plague) 27
  • 28. Clues to a BT Attack•  Illness in animals and humans concurrently•  A large number of unexplained deaths, especially in young healthy adults•  A single case of an uncommon organism (e.g., smallpox, pulmonary anthrax, Ebola)•  Multiple disease entities presenting in one patient•  An unusual disease presentation (e.g., pneumonic instead of bubonic plague) 28
  • 29. Clues to a BT Attack•  An unusual geographic distribution (e.g., Ebola in the U.S.)•  An unusual seasonal pattern (e.g., influenza in summer)•  An illness that fails to respond to usual antimicrobials or vaccines (e.g., engineered antibiotic/vaccine resistant anthrax)•  Clusters of a similar illness in non-contiguous areas, domestic or foreign 29
  • 30. 36 yo female with rash and fever 30
  • 31. Source Undetermined 31
  • 32. Smallpox: Overview•  1980 - Global eradication•  Humans were only known reservoir•  Person-to-person transmission (aerosol/ contact)•  Up to 30% mortality in unvaccinated Source Undetermined 32
  • 33. Smallpox: Clinical Features•  Prodrome (incubation 7-17 days) –  Acute onset of fever, malaise, headache, backache, vomiting, occasional delirium –  Transient erythematous rash•  Exanthem –  Begins face, hands, forearms –  Spread to lower extremities then trunk over ~ 7 days USAMRICD –  Synchronous progression: macules --> vesicles --> pustules --> scabs –  Lesions on palms /soles 33
  • 34. Smallpox Enanthem Illustration of smallpox rash in throat removed 34
  • 35. Day 4 Day 3World Health Organization World Health Organization 35
  • 36. Day 5 Day 7World Health Organization World Health Organization 36
  • 37. Day 8-9 Day 10-14World Health Organization World Health Organization 37
  • 38. World Health Organization 38
  • 39. CDC PHIL # 131 39
  • 40. Source Undetermined 40
  • 41. SMALLPOX CHICKENPOXFEVER 2–4 days before the rash At time of rashRASHAppearance Pocks at same stage Pocks in several stagesDevelopment Slow RapidDistribution More pocks on arms & legs More pocks on bodyOn palms & soles Usually present Usually absentDEATH More than 10% Very uncommon Source Undetermined 41
  • 42. World Health Organization World Health Organization 42
  • 43. •  Smallpox vaccine production using cows Source Undetermined 43
  • 44. 44CDC (All images)
  • 45. 45Logical Images (All Images)
  • 46. Normal ReactionsSource Undetermined 46
  • 47. Staph Infection at Site Dr. V. Fulginiti 47
  • 48. Erythema MultiformeDr. V. Fulginiti Dr. V. Fulginiti Dr. V. FulginitiArthur E. Kaye CDC ID#:3286 Arthur E. Kaye; J. Michael Lane, M.D. CDC PHIL #3318 48
  • 49. Accidental Inoculation Dr. H. Kempe Dr. V. Fulginiti Dr. V. Fulginiti To sites of acne Dr. V. Fulginiti Dr. V. FulginitiDiaper implantation 49
  • 50. Eczema VaccinatumDr. H. Kempe Arthur E. Kaye CDC PHIL #3305Dr. H. Kempe 50
  • 51. Generalized Vaccinia 51Dr. H. Kempe (All Images)
  • 52. Progressive VacciniaChild with Hypogam Child with Hypogam Lymphosarcoma Child with SCID Child with SCID LymphomaDr. V. Fulginiti (All Images) 52
  • 53. Vaccinia KeratitisDr. V. Fulginiti Dr. V. Fulginiti 53
  • 54. Congenital VacciniaSource Undetermined Source Undetermined 3rd Trimester has the highest risk 54
  • 55. Contraindications to Vaccination•  Pregnancy•  Immunodeficiency•  Eczema or Atopic Dermatitis•  Active Skin Conditions•  Active Eye Disease•  Allergy to Components•  Heart Problems 55
  • 56. Additional Source Information for more information see: 4: Stadium: 1000Faces, Wikimedia Commons,; Airplane: Gautherie, Wikimedia Commons,éguet_XIV_au_décollage_La_Ferté_Alais_1994.jpgSlide 8: Admin-2000, Wikimedia Commons,, CC:BY-SA 3.0, 9: UCLA Department of Epidemiology, School of Public Health, 13: USDA, HHS, 15: U.S. Air Forces in Europe,, Sources Undetermined (All other Images)Slide 17: Lesion: Source Undetermined, Thumb: CDC, X-Ray: Cornell University Medical CollegeSlide 18: C. botulinum: Source Undetermined; Image of botox injection is available here: 19: Dr. Lyle Conrad, Joel G. Breman, CDC PHIL #7201; Source UndeterminedSlide 20: (From left to right) Source Undetermined; World Health Organization, CDC PHIL #463; CDC PHIL #2047; Source UndeterminedSlide 21: Sources UndeterminedSlide 22: Source UndeterminedSlide 23: 18th century London newspaperSlide 31: Source UndeterminedSlide 32: Source UndeterminedSlide 35: World Health Organization, (All images)Slide 36: World Health Organization, (All images)Slide 37: World Health Organization, (All images)Slide 38: World Health Organization, (All images)Slide 39: CDC PHIL # 131, 40: Source UndeterminedSlide 41: Source UndeterminedSlide 42: World Health Organization, (All images)Slide 43: Source UndeterminedSlide 44: CDC, 45: Logical Images (All Images), 46: Source UndeterminedSlide 47: Dr. V. FulginitiSlide 48: Dr. V. Fulginiti; Dr. V. Fulginiti; Dr. V. Fulginiti; Arthur E. Kaye CDC ID#:3286; Arthur E. Kaye; J. Michael Lane, M.D. CDC PHIL #3318Slide 49: Dr. H. Kempe; Dr. V. Fulginiti; Dr. V. Fulginiti; Dr. V. Fulginiti; Dr. V. Fulginiti;Slide 50: Dr. H. Kempe; Dr. H. Kempe; Arthur E. Kaye CDC PHIL #3305Slide 51: Dr. H. Kempe (All Images)Slide 52: Dr. V. Fulginiti (All Images)Slide 53: Dr. V. Fulginiti; Dr. V. FulginitiSlide 54: Sources Undetermined